From rxpgnews.com
NDA accepted to review Indiplon for the treatment of insomnia
By Neurocrine Biosciences, Inc.,
Jul 27, 2005 - 1:43:38 PM
Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for indiplon tablets for review for the treatment of insomnia in both adult and elderly patients.
"This is an exciting milestone for Neurocrine and represents the company's first completed NDA filing," said Gary A. Lyons, President and CEO of Neurocrine Biosciences. "Data from these two submissions is supported by one of the most comprehensive clinical trial programs in insomnia and demonstrates the long-term safety and efficacy profile of indiplon in helping patients with sleep onset and sleep maintenance problems."
Indiplon is a unique non-narcotic, non-benzodiazepine agent that acts on a specific site of the GABA-A receptor. Indiplon has been shown to bind selectively to the specific subtype of GABA-A receptors within the brain believed to be responsible for promoting sleep. Indiplon was developed to address different types of sleep problems. Upon approval, indiplon will be copromoted in the US with Pfizer.
Insomnia is a prevalent condition in the United States. According to the National Sleep Foundation's (NSF) Sleep in America Poll 2005 approximately half of America's adults report that they experienced at least one symptom of insomnia a few nights a week or more in the past year. Sleep loss has been found to impair the ability to perform tasks involving memory, learning, and logical reasoning, yet few people understand the importance of sufficient sleep.
All rights reserved by RxPG Medical Solutions Private Limited ( www.rxpgnews.com )